Navigation Links
UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGo's Platform
Date:1/8/2008

ST. JOSEPH, Mich., Jan. 8 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that UC Berkeley will expand the use of its MetaCore/MetaDrug Discovery Platform in their Computational Toxicology course, a required component for Molecular Toxicology majors, and in undergrad honors research programs. The agreement will provide students with chemical structure, network and pathway analysis tools needed to analyze complex omics datasets and to predict and understand the beneficial and potentially harmful effects of chemicals in humans and other species.

"When we designed our Computational Toxicology course a few years ago we anticipated a shift in the future toward 'systems biology' that is, looking at the complex interactions of metabolic, genetic, protein, and cellular elements with the goal of modeling entire systems in relation to chemical stresses," said Dale Johnson, Pharm.D., Ph.D., Adjunct Professor, who designed and teaches the Computational Toxicology course. "The complexity of these chemical/biological interactions resulting from environmental exposures, food sources, or pharmaceutical compounds, highlights our thinking that an overall systems approach will be necessary if relevant advances are to be made in applying computational solutions. GeneGo has presented us with an outstanding platform that continues to grow in functionality each year. We are extremely pleased to be able to utilize MetaCore/MetaDrug as the core part of our coursework."

"We are pleased with the decision of UC Berkeley's Department of Nutritional Sciences and Toxicology to include our tools in its curriculum, which is one of the very best in the world," said Julie Bryant, Vice President of Business Development for GeneGo. "The study of fundamental biology is changing quickly with omics technology and systems level analysis, and these changes affect application fields such as toxicology. UC Berkeley will be educating a new breed of toxicology researchers that are needed for the future success of taking drugs to market."

"Today's drug and chemical safety assessment process increasingly leverages information from many different sources," said Dr. Richard Brennan, GeneGo's Director of Toxicology. "Molecular toxicologists need to be able to put traditional toxicology measurements in the context of chemical information as well as biochemical, gene expression, protein and metabolite data. Industry needs scientists well-versed in complex systems biology data, and in the powerful and flexible analysis tools increasingly used in safety assessment. UC Berkeley is leading the way in providing training in current and emerging technologies, and we are pleased to be able to contribute to this cutting-edge program."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) and MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Immune Support Formula Licensed From UC Berkeley Launched
2. Observant LLC Expands Senior Management Team
3. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
4. HealthTrust Expands Contract With Instrumentation Laboratory for Critical Care Portfolio to Include Consorta
5. CSL Behring Expands Into Middle East Market with Haemate(R) P
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
8. Siemens Expands the SOMATOM Definition(TM) Line With Worlds First Adaptive CT Scanner
9. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
10. Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market
11. Imaging Diagnostic Systems Expands Key Patent Coverage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):